CD64 binding potential does not translate into enhanced therapeutic efficacy for anti-IL-23 antibodies under physiologically relevant conditions

Abstract Background Interleukin (IL)-23 neutralizing antibodies are clinically efficacious but differ in the functionality of their Fc portion. Guselkumab (GUS) and ustekinumab (UST) have a wild-type (WT) Fc portion, permitting native binding to Fc gamma receptors (FcγRs), while risankizumab (RZB) l...

Descripció completa

Dades bibliogràfiques

Autors principals:	Joel F. Cohen-Solal, Calvin S. Pohl, Sheila M. Cummings, Jeremy P. Gygi, Zhaleh Safikhani, Brigitte Bartocha, Christopher D. Buckley, Yongli Dong, Killian Eyerich, Samuel D. Karsen, Grace R. Lynch, Michael Macoritto, Pierre A. Morisset, Ornella D. Nelson, Timothy Radstake, Florian Rieder, Jocelyn Rivas, John P. Savaryn, Kathleen M. Smith, Madison Stulir, Carmin Szynal, Casey Tylek, Geertruida M. Veldman, Laura G. Wasserman, Susan Westmoreland, Neha Chaudhary, Matthew M. Staron
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2026-03-01
Col·lecció:	Molecular Medicine
Matèries:	CD64 Crohn’s disease Fc portion FcγRI Guselkumab Inflammatory bowel disease
Accés en línia:	https://doi.org/10.1186/s10020-026-01462-z
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!